Does MRI lesion activity regress in secondary progressive multiple sclerosis?

Subscribe to email list

Please select the email list(s) to which you wish to subscribe.

You are here

Does MRI lesion activity regress in secondary progressive multiple sclerosis?

TitleDoes MRI lesion activity regress in secondary progressive multiple sclerosis?
Publication TypeJournal Article
Year of Publication2010
AuthorsZhao, Y, Petkau, AJ, Traboulsee, A, Riddehough, A, Li, DKB
JournalMultiple Sclerosis
Date Publishedfeb
ISSN1352-4585, 1477-0970
AbstractBackground: The rate of new contrast-enhancing lesions (CELs) on monthly magnetic resonance imaging (MRI) scans has been shown to decrease over a 9-month period in placebo-treated patients with relapsing–remitting (RR) multiple sclerosis (RRMS). Objective: We examined this phenomenon in placebo-treated secondary progressive MS (SPMS) patients. Methods: Patients were chosen from two clinical trials. Monthly scans were taken at screening, baseline and months 1–9 for Cohort-1 and months 1–6 for Cohort-2. We examined the monthly new CEL rates according to initial CEL level: 0, 1–3, >3 CELs at screening, and presence and absence of pre-study relapses. Results:Respectively, 59, 21 and 14 of the 94 Cohort-1 patients, and 36, 17 and 9 of the 62 Cohort-2 patients had 0, 1–3 and >3 initial CELs. For Cohort-1, the monthly new CEL rates did not change during follow-up, regardless of initial CEL level. For Cohort-2, the monthly rate was unchanged in the 0 initial CEL subgroup, but decreased 33% (95% confidence interval: 8%, 52%) from months 1–3 to months 4–6 in the other two subgroups. For the combined cohorts, a decreasing rate was observed in the 12 patients with >3 initial CELs and pre-study relapses. Conclusions: The short-term trend of new CEL activity in placebo-treated SPMS patients may vary across cohorts.
URLhttp://msj.sagepub.com/content/early/2010/02/18/1352458509359726
DOI10.1177/1352458509359726